Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron)

2 December 2021

Intervista al Presidente FIT Giorgio Calderari, Falò RSI La 1, giovedì 25 novembre 2021

26 November 2021

BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types

19 November 2021

Farma Industria Ticino in Milan for CPhI 2021, 9-11 November 2021

15 November 2021

Helsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR

12 October 2021

Helsinn Group announces oral presentation of data at AACR-NCI- EORTC relating to a potent and highly selective investigational RET inhibitor

7 October 2021

Site Selection for Life Sciences Companies in Europe – 2021 edition out now

7 October 2021

Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQTM (infigratinib) for Patients with Cholangiocarcinoma

29 September 2021

41a Assemblea generale ordinaria di Farma Industria Ticino

13 September 2021

Comunicato Stampa premiazione Farma Industria Ticino

10 September 2021